Assembly Biosciences (ASMB) Net Cash Flow (2010 - 2026)
Assembly Biosciences (ASMB) posted quarterly Net Cash Flow of -$27.3 million for Q1 2026, down 83.04% year-over-year from -$161.2 million in Q1 2025, and down 176.09% quarter-over-quarter from $35.9 million in Q4 2025.
Assembly Biosciences (ASMB) Net Cash Flow (2010 - 2026) Analysis & Trends
Assembly Biosciences' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$27.3 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 83.04% year-over-year to -$27.3 million; the TTM figure through Mar 2026 stood at $7.7 million (up 65.24% YoY), while the FY2025 annual figure was $20.1 million, up 8.66% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$27.3 million, down from $35.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $35.9 million in Q4 2025, with the low at -$27.3 million in Q1 2026.
- The 5-year median for Net Cash Flow is -$1.1 million (2024), against an average of -$853352.9.
- Peak annual rise in Net Cash Flow reached 263.08% in 2025, while the deepest fall reached 1267.31% in 2025.
- Assembly Biosciences' Net Cash Flow stood at -$2.3 million in 2022, then slumped by 202.22% to -$6.8 million in 2023, then surged by 245.15% to $9.9 million in 2024, then surged by 263.08% to $35.9 million in 2025, then plunged by 176.09% to -$27.3 million in 2026.
- Business Quant data shows ASMB's Net Cash Flow at -$27.3 million in Q1 2026, $35.9 million in Q4 2025, and -$1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | 1.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.17 Mn |
| Jun 30, 2026 | 1.17 Mn |
| Mar 31, 2026 | -27.33 Mn |
| Mar 31, 2026 | -27.33 Mn |
| Dec 31, 2025 | 35.92 Mn |
| Dec 31, 2025 | 35.92 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Sep 30, 2025 | -1.47 Mn |
| Jun 30, 2025 | 593,000.00 |
| Jun 30, 2025 | 593,000.00 |
| Mar 31, 2025 | -14.93 Mn |
| Mar 31, 2025 | -14.93 Mn |
| Dec 31, 2024 | 9.89 Mn |
| Dec 31, 2024 | 9.89 Mn |
| Sep 30, 2024 | 9.24 Mn |
| Sep 30, 2024 | 9.24 Mn |
| Jun 30, 2024 | 459,000.00 |
| Jun 30, 2024 | 459,000.00 |
| Mar 31, 2024 | -1.09 Mn |
| Mar 31, 2024 | -1.09 Mn |